Suppr超能文献

一名患有严重再生障碍性贫血的5岁男孩在接受来自无关供体的第二次骨髓移植后,其淋巴增生性疾病得到缓解。

Remission of a lymphoproliferative disorder occurring after second BMT from an unrelated donor in a 5-year-old boy with severe aplastic anemia.

作者信息

Bader P, Klingebiel T, Klingel K, Föll J, Beck J, Handgretinger R, Ehninger G, Deeg H J, Niethammer D

机构信息

Children's University Hospital, Dept. Hematology/Oncology, Tübingen, Germany.

出版信息

Bone Marrow Transplant. 1995 Sep;16(3):479-81.

PMID:8535324
Abstract

A 5-year-old boy with severe aplastic anemia failed to respond to cyclosporine (CYA), prednisolone and antilymphocyte globulin (ALG). No suitable sibling marrow donor was available, but an HLA-matched unrelated donor was identified. The patient was conditioned with cyclophosphamide (CY), 50 mg/kg/day for 4 days, total nodal irradiation (8 Gy), and ALG 30 mg/kg/day for 3 days. GVHD prophylaxis consisted of daily CYA, methotrexate (MTX) and ALG. The patient failed to achieve sustained engraftment. He was reconditioned with high-dose prednisolone and anti-T lymphocyte monoclonal antibody OKT3. The boy was reinfused with the same donor marrow on day 0 (+49/first BMT). No GVHD prophylaxis was given the second time. He received G-CSF on days 0 to +20 after the second transplant. Full engraftment was achieved on day +16 (+65). However, on day +31 (80) he developed a biopsy-proven B cell lymphoproliferative disorder (BLPD). After the OKT3 administration was stopped and treatment with ganciclovir and high-dose immunoglobulin was initiated, the BLPD resolved and the patient was discharged on day +50 (99). He is currently well with a functioning graft 266 (305) days posttransplant, with no sign of GVHD.

摘要

一名5岁的重度再生障碍性贫血男孩对环孢素(CYA)、泼尼松龙和抗淋巴细胞球蛋白(ALG)治疗无反应。没有合适的同胞骨髓供者,但找到了一名HLA匹配的无关供者。患者接受环磷酰胺(CY)预处理,50mg/kg/天,共4天,全身淋巴结照射(8Gy),以及ALG 30mg/kg/天,共3天。移植物抗宿主病(GVHD)预防措施包括每日使用CYA、甲氨蝶呤(MTX)和ALG。患者未能实现持续植入。他接受了大剂量泼尼松龙和抗T淋巴细胞单克隆抗体OKT3的再次预处理。该男孩在第0天(+49/首次骨髓移植)再次输注了同一供者的骨髓。第二次未采取GVHD预防措施。第二次移植后第0天至+20天他接受了粒细胞集落刺激因子(G-CSF)治疗。在第+16天(+65)实现了完全植入。然而,在第+31天(80),他经活检证实发生了B细胞淋巴增殖性疾病(BLPD)。在停用OKT3并开始使用更昔洛韦和大剂量免疫球蛋白治疗后,BLPD得到缓解,患者于第+50天(99)出院。目前,移植后266(305)天他情况良好,移植物功能正常,无GVHD迹象。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验